Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;27(12):811-820.
doi: 10.1007/s11916-023-01185-4. Epub 2023 Oct 28.

Buprenorphine for Chronic Pain Management: a Narrative Review

Peter D Vu  1 , Vishal Bansal  1 , Ahish Chitneni  2 , Christopher L Robinson  3 , Omar Viswanath  4 , Ivan Urits  4 , Alan D Kaye  4 , Anvinh Nguyen  5 , Ranganathan Govindaraj  6 , Grant H Chen  6 , Jamal Hasoon  7
Affiliations
Review

Buprenorphine for Chronic Pain Management: a Narrative Review

Peter D Vu et al. Curr Pain Headache Rep. 2023 Dec.

Abstract

Purpose of review: The aim of this review is to educate healthcare professionals regarding buprenorphine for the use of opioid use disorder (OUD) as well as for chronic pain management. This review provides physicians and practitioners with updated information regarding the distinct characteristics and intricacies of prescribing buprenorphine.

Recent findings: Buprenorphine is approved by the US Food and Drug Administration (FDA) for acute pain, chronic pain, opioid use disorder (OUD), and opioid dependence. When compared to most other opioids, buprenorphine offers superior patient tolerability, an excellent half-life, and minimal respiratory depression. Buprenorphine does have notable side effects as well as pharmacokinetic properties that require special attention, especially if patients require future surgical interventions. Many physicians are not trained to initiate or manage patients on buprenorphine. However, buprenorphine offers a potentially safer alternative for medication management for patients who require chronic opioid therapy for pain or have OUD. This review provides updated information on buprenorphine for both chronic pain and OUD.

Keywords: Buprenorphine; Chronic opioid therapy; Chronic pain; Opioid use disorder; Opioids.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Dahlhamer J, Lucas J, Zelaya, Carla, et al. Prevalence of chronic pain and high-impact chronic pain among adults — United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–1006. https://doi.org/10.15585/mmwr.mm6736a2 .
    1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. U.S. Department of Health and Human Services.
    1. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405–16. https://doi.org/10.1037/a0013628 . - DOI - PubMed - PMC
    1. Dalal S, Chitneni A, Berger AA, et al. Buprenorphine for chronic pain: a safer alternative to traditional opioids. Health Psychol Res. 2021;9(1). https://doi.org/10.52965/001c.27241 .
    1. Poliwoda S, Noor N, Jenkins JS, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3). https://doi.org/10.52965/001c.37517 .

MeSH terms

LinkOut - more resources